Circulating immune parameters-based nomogram for predicting malignancy in laryngeal neoplasm.

paythelady.612 shared this article with you from Inoreader Circulating immune parameters-based nomogram for predicting malignancy in laryngeal neoplasm. Μέσω pubmed: "world j clin cases"... Related Articles Circulating immune parameters-based nomogram for predicting malignancy in laryngeal neoplasm. World J Clin Cases. 2021 Jan 26;9(3):540-551 Authors: Chen M, Fang Y, Yang Y, He PJ, Cheng L, Wu HT Abstract BACKGROUND: Malignancy prediction remains important to preoperative diagnosis and postoperative follow-up in laryngeal neoplasm. AIM: To evaluate the circulating immune population and develop a nomogram for prediction of malignancy in patients with laryngeal neoplasm. METHODS: A primary cohort of 156 patients was divided into laryngeal benign lesion, premalignant lesion and malignant lesion groups. Peripheral blood from patients was measured by blood routine test and flow cytometry. A nomogram was developed and applied to a validation cohort containing 55 consecutive patients. RESULTS: Age, gender and seven circulating immune parameters exhibited significant differences between laryngeal benign lesion and premalignant lesion. The nomogram incorporated predictors, including gender, age, smoke index, proportions of monocytes, CD8+ T cells, CD4+ T cells, B cells and CD4/CD8+ T cell ratio. It showed good discrimination between laryngeal premalignant lesion and malignant lesion, with a C-index of 0.844 for the primary cohort. Application of this nomogram in the validation cohort (C-index, 0.804) still had good discrimination and good calibration. Decision curve analysis revealed that the nomogram was clinically useful. CONCLUSION: This novel nomogram, incorporating both clinical risk factors and circulating immune parameters, could be appropriately applied in preoperative individualized prediction of malignancy in patients with laryngeal neoplasm. PMID: 33553392 [PubMed] View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.